P
BIIB icon

&Partners’s Biogen BIIB Stock Holding History

&Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$893K Buy
5,037
+752
+18% +$139K ﹤0.01% 1366
2025
Q4 		$833K Buy
4,285
+755
+21% +$123K ﹤0.01% 1325
2025
Q3 		$494K Buy
3,530
+671
+23% +$90.7K ﹤0.01% 1450
2025
Q2 		$361K Buy
2,859
+1,076
+60% +$134K ﹤0.01% 1526
2025
Q1 		$247K Buy
1,783
+62
+4% +$8.86K ﹤0.01% 1514
2024
Q4 		$262K Sell
1,721
-475
-22% -$80.1K ﹤0.01% 1408
2024
Q3 		$431K Buy
2,196
+939
+75% +$196K 0.01% 934
2024
Q2 		$291K Buy
+1,257
New +$273K 0.01% 723

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

&Partners's BIIB Position: Q1 2026 in Review

&Partners increased its Biogen (BIIB) stake by 18% in Q1 2026, buying an estimated $139K and bringing the position to 5,037 shares worth $893K. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

&Partners first reported a position in BIIB in Q2 2024 and has held it in 8 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • &Partners held 5,037 shares of Biogen worth $893K as of Q1 2026.
  • &Partners bought 752 Biogen shares in Q1 2026, an estimated $139K.
  • Biogen made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1366 holding.
  • &Partners first reported a position in Biogen in Q2 2024 and has held it in 8 quarters since.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.